NasdaqCM:RZLT
NasdaqCM:RZLTBiotechs

Is Rezolute (RZLT) Using sunRIZE Phase 3 And Shelf Filing To Quietly Recast Its Strategy?

Rezolute recently scheduled a special call to discuss results from its Phase 3 sunRIZE study in congenital hyperinsulinism, a rare pediatric disorder with significant unmet medical need. The combination of pivotal trial readout and a broad shelf registration filing highlights how Rezolute may be preparing for potential commercialization and future financing flexibility. With Phase 3 sunRIZE data in focus, we’ll now examine how this potential inflection point could reshape Rezolute’s overall...
NYSE:CAH
NYSE:CAHHealthcare

Is Cardinal Health Still Attractively Priced After Its Huge 2025 Run And DCF Upside?

If you are wondering whether Cardinal Health is still a smart buy after its massive run, or if you are arriving late to the party, this breakdown will help you think through whether the current price makes long term sense. The stock has cooled slightly in the short term, slipping around 0.8% over the last week and 3.5% over the last month, but it is still up roughly 67.9% year to date and about 71.2% over the last year, capping a 315.0% gain over five years. Recent headlines have focused on...
NYSE:HRB
NYSE:HRBConsumer Services

Is H&R Block’s Recent 21% Slide Creating a Long Term Opportunity for Investors

Wondering if H&R Block is quietly becoming a bargain, or if the market is signaling deeper issues with the business? This breakdown will help you decide whether HRB deserves a spot on your watchlist. The stock has slipped recently, down 2.4% over the last week, 12.5% over the past month, and 21.4% year to date. However, longer term holders are still sitting on gains of 9.2% over 3 years and 209.2% over 5 years. Some of this pullback reflects shifting sentiment around consumer services and...
NasdaqGS:CME
NasdaqGS:CMECapital Markets

Is CME Group Still Attractive After Its Strong Multi Year Share Price Rally?

If you have been wondering whether CME Group is still worth buying after this long run up, you are not alone. This article is going to unpack what the current price really implies. Even after a recent pullback of around 2.9% over the last week and 3.9% over the last month, the stock is still up 14.4% year to date and about 18.2% over the past year, building on a powerful 74.0% three year and 78.8% five year climb. Those moves have come as CME continues to sit at the center of global...
NYSE:CNS
NYSE:CNSCapital Markets

Is Cohen and Steers Share Slide in 2025 Creating a Long Term Opportunity?

If you are wondering whether Cohen & Steers is a value trap or a quiet opportunity hiding in plain sight, this breakdown can help you assess whether the current share price really lines up with the underlying business. The stock has drifted lower recently, with shares down 0.9% over the last week, 7.6% over the past month, and 32.3% year to date. This naturally raises questions about whether sentiment has moved beyond what the fundamentals justify. Much of the move is tied to shifting...
NasdaqGS:ADSK
NasdaqGS:ADSKSoftware

Is Autodesk Fairly Priced After Its Cloud Push and Mixed 2025 Growth Signals?

If you have ever wondered whether Autodesk is actually worth its current price tag, you are not alone. This article is designed to unpack what the market might be missing. The stock has been choppy lately, slipping around 2.3% over the last week and only 0.5% over the past month, but it is still up about 2.3% year to date and 50.0% over three years. This hints at a longer term growth story despite a slightly negative 1 year return of 2.4%. Recent attention on Autodesk has centered on its...
NYSE:AI
NYSE:AISoftware

Evaluating C3.ai (AI) After Its New U.S. Army Logistics Deal: Does The Valuation Still Look Stretched?

C3.ai (AI) just landed a meaningful endorsement from the U.S. Army’s Rapid Capabilities and Critical Technologies Office, which is adopting its AI platform to manage contested logistics and keep front line units supplied. See our latest analysis for C3.ai. Even with marquee wins like the Army and a new HHS data platform deal, C3.ai’s share price return has slid sharply this year, with the latest close at $15.82. Its three year total shareholder return is still positive, suggesting long term...
NYSE:RDW
NYSE:RDWAerospace & Defense

Redwire’s Recent 34% Surge Versus DCF and Sales Metrics in 2025

If you are wondering whether Redwire at around $7.50 is a bargain or a value trap, you are not alone. That is exactly what we are going to unpack. The stock has jumped 34.3% over the last week and 21.2% over the past month, but it is still down 56.1% year to date and 35.9% over the last year, even after a 3 year gain of 281.6%. Those swings have come as investors digest a steady drumbeat of contract wins and broader enthusiasm for space infrastructure and defense related spending, which have...
NasdaqGS:STX
NasdaqGS:STXTech

A closer look at Seagate Technology’s (STX) valuation after insider selling and renewed institutional buying interest

Insider selling after a 300% rally at Seagate Technology Holdings (STX) has grabbed attention, but the bigger story is that institutional buyers are still stepping in as analysts stay broadly constructive. See our latest analysis for Seagate Technology Holdings. That backdrop helps explain why the stock’s latest move, with a 1 day share price return of 5.68 percent and a 7 day share price return of 15.56 percent, comes on top of a powerful year to date share price return of 246.01 percent and...
NYSE:FND
NYSE:FNDSpecialty Retail

Is Floor & Decor (FND) Prioritizing Store Expansion Over Maximizing Returns On Existing Locations?

In the past week, Floor & Decor Holdings reported a mixed quarter with revenue rising 5.5% while comparable sales slipped 1.2%, as management cut store buildout costs, managed a CEO transition, and reaffirmed plans to open about 20 stores annually despite housing market pressures. At the same time, the company is leaning into digital innovation, expanded kitchen and outdoor offerings, and supply chain improvements to capture market share even as weak same-store sales and an 8.8% return on...
NasdaqGS:LYFT
NasdaqGS:LYFTTransportation

Is Lyft Still a Comeback Story After Its 2025 Rally and Recent Pullback?

Wondering if Lyft at around $20 a share is still a comeback story in the making, or if the easy money has already been made? You are not alone, and that is exactly what we are going to unpack here. Despite a sharp pullback over the last week and month, with the stock down 9.8% over 7 days and 16.0% over 30 days, Lyft is still up 48.9% year to date and 36.8% over the past year. This highlights how quickly sentiment around the name can swing. Recent headlines have focused on Lyft sharpening...
NYSE:AAT
NYSE:AATREITs

Taking Stock of American Assets Trust (AAT) After Argosy Stake and Raised FFO Guidance

American Assets Trust (AAT) just attracted a fresh $4.4 million stake from Argosy-Lionbridge Management, right after the REIT nudged its full year FFO guidance higher, a combination that naturally draws value focused investors. See our latest analysis for American Assets Trust. The new Argosy-Lionbridge stake and slightly higher FFO guidance land against a weaker backdrop, with a year to date share price return of negative 26.9 percent and a one year total shareholder return of negative 26.55...
NYSE:PRMB
NYSE:PRMBBeverage

Primo Brands (PRMB): Assessing Valuation After a 50% Share Price Slide

Primo Brands (PRMB) has quietly slid almost 50% over the past year, even as its annual revenue still edges higher and earnings swing sharply. That disconnect is exactly what has value focused investors paying closer attention. See our latest analysis for Primo Brands. Over the past year, Primo Brands’ 1 year total shareholder return of around negative 50 percent, alongside a roughly negative 35 percent 3 month share price return from about 15 dollars, suggests sentiment has been fading even...
NYSE:MMC
NYSE:MMCInsurance

Is Marsh & McLennan Still Attractive After a 15% Pullback and Mixed Valuation Signals?

Wondering if Marsh & McLennan Companies is still worth buying after a long run up, or if the market has finally pushed this blue chip too far? This article will walk through what the current share price really implies about future returns. The stock has drifted lower recently, with shares down 1.2% over the last week, 0.5% over the last month, and about 14.9% over the past year, even though the 3 year and 5 year returns of 12.5% and 64.1% still show a solid long term compounding story. That...
NasdaqGS:LINE
NasdaqGS:LINEIndustrial REITs

How Lineage’s US$450 Million LinOS Investment and EBITDA Targets Could Impact Lineage (LINE) Investors

Earlier this month, Lineage outlined its operational excellence and digital strategy, emphasizing the rollout of its proprietary LinOS warehouse execution system to more than 250 locations by 2029 and projecting about US$110 million in incremental annual EBITDA over the next three to five years. The company has already invested US$250 million in LinOS, committed a further US$200 million through 2030, and is targeting a forecasted return on invested capital of 24%, while also linking recent...
NYSE:H
NYSE:HHospitality

How Investors May Respond To Hyatt Hotels (H) Tapping Asilia Safaris To Deepen Asset-Light Luxury Loyalty

Earlier this month, Hyatt Hotels Corporation expanded its luxury offerings by enabling World of Hyatt members to book 15 Asilia Africa safari camps across Kenya, Tanzania, and Uganda via Hyatt’s channels, while also appointing Puneet Baijal as General Manager of Hyatt Regency Mumbai. This move extends Hyatt’s loyalty ecosystem into high-end experiential travel and aligns the brand with community-led conservation, which may appeal to environmentally conscious premium guests. Next, we’ll...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

United Therapeutics (UTHR): Valuation Check After Insider Sales and Mixed Revenue Versus Analyst Expectations

United Therapeutics (UTHR) is back in focus after several senior executives disclosed sizable stock sales, including Chairperson and CEO Martine Rothblatt, prompting investors to reassess what this insider activity might signal for the shares. See our latest analysis for United Therapeutics. The insider moves are landing against a backdrop of strong momentum, with a roughly 19.7 percent 3 month share price return and about 226.6 percent 5 year total shareholder return, suggesting investors...
NYSE:FLS
NYSE:FLSMachinery

Does D1’s Bigger Bet and Rising Aftermarket Mix Change The Bull Case For Flowserve (FLS)?

Earlier this quarter, New York-based D1 Capital Partners lifted its stake in Flowserve by nearly 5.8 million shares to about 7.5 million, a position valued at roughly US$397.5 million at quarter-end. This move came alongside Flowserve reporting consistent operations, expanding margins, stronger cash generation, and a higher mix of aftermarket revenue, underscoring rising confidence in its business quality. We’ll now examine how D1’s larger ownership position and Flowserve’s margin and cash...
NYSE:HESM
NYSE:HESMOil and Gas

How Investors May Respond To Hess Midstream (HESM) 2026 Outlook And Chevron-Aligned Board Shake-Up

Hess Midstream LP recently outlined its 2026 outlook, guiding to net income of US$650 million–US$700 million with largely steady oil and gas throughput, while also significantly trimming capital spending and signaling continued distribution growth backed by free cash flow. At the same time, the company reshaped its board by naming existing director Kristi McCarthy as chair and adding Chevron executive Barbara Harrison, moves that tighten its alignment with Chevron’s long-term plans for...
NasdaqGM:RAPP
NasdaqGM:RAPPPharmaceuticals

How Investors May Respond To Rapport Therapeutics (RAPP) Advancing RAP-219 Toward Phase 3 After Positive Phase 2a Data

Rapport Therapeutics recently reported additional Phase 2a data for its epilepsy candidate RAP-219, showing statistically significant improvements in seizure severity and patient-reported functioning in adults with drug-resistant focal onset seizures, and outlined plans to start two pivotal Phase 3 trials in 2026 following an upcoming end-of-Phase 2 meeting with the FDA. An interesting element for investors is the PET receptor occupancy data, which links RAP-219’s brain target engagement to...
NYSE:TROX
NYSE:TROXChemicals

Tronox Holdings (NYSE:TROX): Valuation Check After Major Government-Backed Financing for Rare Earths Expansion

Tronox Holdings (NYSE:TROX) is back on investor radar after lining up up to $600 million in potential government backed financing to expand its rare earths supply chain across Australian mining and processing assets. See our latest analysis for Tronox Holdings. The news lands at an interesting moment for Tronox, with the latest $4.52 share price sitting well below where it started the year. This comes despite a sharp 30 day share price return of 25.21 percent, which suggests momentum may be...
NasdaqGS:IRDM
NasdaqGS:IRDMTelecom

Reassessing Iridium Communications After a 36% Slide and Recent Share Price Rebound

If you have been wondering whether Iridium Communications is starting to look like a bargain or just a value trap, you are not alone, and this is exactly the kind of stock where valuation really matters. The share price has bounced 7.5% over the last week and 12.7% over the past month, but it is still down 36.2% year to date and 36.6% over the last year. That suggests sentiment has shifted, but conviction is still fragile. Those moves come against a backdrop of ongoing interest in satellite...
NYSE:LUMN
NYSE:LUMNTelecom

The Bull Case For Lumen Technologies (LUMN) Could Change Following Debt Refi And Security Push – Learn Why

Lumen Technologies recently outlined a major debt refinancing, with its Level 3 Financing unit upsizing a senior notes offering to US$1.25 billion due 2036 and launching tender offers to retire existing second lien notes, alongside leadership changes that will see board member James Fowler become executive vice president, chief technology and product officer in early 2026. At the same time, Lumen is pushing deeper into security and cloud ecosystems through Black Lotus Labs–powered Defender...
NYSE:LOAR
NYSE:LOARAerospace & Defense

Loar’s Expanded Undrawn Credit Capacity Might Change The Case For Investing In Loar Holdings (LOAR)

On November 25, 2025, Loar Holdings Inc. amended its Credit Agreement, increasing its delayed draw term loan commitment by US$175.0 million to US$275.0 million and extending the availability period through September 30, 2026, leaving the full US$275.0 million still undrawn as of that date. This expanded and extended loan capacity, together with fresh analyst coverage positioning Loar as a high-quality aerospace aftermarket M&A compounder, enhances the company’s financial flexibility to...